A phase I study of sorafenib, oxaliplatin and two days of high dose capecitabine in advanced pancreatic and biliary tract cancer: A Wisconsin Oncology Network Study

Chemotherapy has yielded minimal clinical benefit in pancreatic and biliary tract cancer. A high-dose, short course capecitabine schedule with oxaliplatin, has shown some efficacy with a lower incidence of palmar-plantar erythrodysesthesia. Achieving high exposures of the targeted agent sorafenib ma...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: LoConte, Noelle K., Holen, Kyle D., Schelman, William R., Mulkerin, Daniel L., Deming, Dustin A., Hernan, Hilary R., Traynor, Anne M., Goggins, Timothy, Groteluschen, David, Oettel, Kurt, Robinson, Emily, Lubner, Sam J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2012
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4199231/
https://ncbi.nlm.nih.gov/pubmed/23263993
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-012-9916-5
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg